294 completed. 294 Phase 2, 35 Phase 1, 35 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 294 | Completed 294 |
| Phase 1 | 35 | Completed 35 |
| Phase 3 | 35 | Completed 35 |
Follow Dyssomnias: new trials by email Literature Review of Dyssomnias trials Research Report on Dyssomnias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances RE03, Placebo - Posttraumatic Stress Disorder (PTSD), Sleep Disturbances and Insomnia | Phase 2 | Completed | Reconnect Labs | 12 | 2025-09-30 | 2026-07-23 |
| A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension Lorundrostat, Placebo - Obstructive Sleep Apnea, Hypertension | Phase 2 | Completed | Mineralys Therapeutics Inc. | 48 | 2025-02-28 | 2026-08-21 |
| Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems Lemborexant, Placebo - Cirrhosis, Liver Cirrhosis | Phase 2 | Completed | Universitas Indonesia | 82 | 2024-10-01 | 2026-03-18 |
| RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) Modafinil, Modafinil Placebo, Solriamfetol - Long COVID, Long COVID-19 | Phase 2 | Completed | Duke University | 361 | 2024-08-12 | 2026-06-03 |
| RECOVER-SLEEP: Platform Protocol Modafinil, Modafinil Placebo, Solriamfetol - Long COVID, Long COVID-19 | Phase 2 | Completed | Duke University | 830 | 2024-07-31 | 2026-01-22 |
| A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 ALKS 2680, Placebo - Narcolepsy Type 2 | Phase 2 | Completed | Alkermes, Inc. | 93 | 2024-07-26 | 2026-02-27 |
| CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial Cognitive Behavioral Therapy for Insomnia - Primary Brain Tumor, Glioblastoma | Phase 2 | Completed | Virginia Commonwealth University | 70 | 2024-07-08 | 2025-10-01 |
| Study That Tests AD109 in Patients Taking GLP-1 Drugs AD109 - OSA | Phase 2 | Completed | Apnimed | 40 | 2024-05-20 | 2025-02-19 |
| RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA IHL-42X Low Dose, IHL-42X High Dose, Placebo - Obstructive Sleep Apnea | Phase 2 / Phase 3 | Completed | Incannex Healthcare Ltd | 121 | 2024-05-02 | 2026-07-27 |
| The CanISleepinMS Study: Effect of Cannabidiol (CBD) on Sleep Quality in Patients With Multiple Sclerosis Cannabidiol Oil - Sleep Quality, Multiple Sclerosis | Phase 2 | Completed | Wageningen University | 16 | 2024-03-26 | 2026-09-25 |
| A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) ALKS 2680, Placebo - Narcolepsy Type 1 | Phase 2 | Completed | Alkermes, Inc. | 92 | 2024-03-24 | 2026-06-10 |
| Effect of Diaphragmatic Breathing Exercise on Pain and Sleep Quality in Individuals With Non-specific Chronic Neck Pain: A Randomized Control Trial diaphragmatic breathing exercise, conventional physiotherapy exercise - Non-specific Chronic Neck Pain, Diaphragmatic Breathing Exercise | Phase 2 | Completed | University of Jordan | 40 | 2024-03-01 | 2024-06-25 |
| Managing Opioid Related Sleep Apnea With Acetazolamide Acetazolamide, Placebo - Sleep-Disordered Breathing, Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 39 | 2023-10-18 | 2026-03-10 |
| Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes Baseline surveys, Cognitive testing and EMAs, Actiwatch, suvorexant (or placebo) - Insomnia | Phase 2 | Completed | University of Maryland, Baltimore | 40 | 2023-10-09 | 2025-10-30 |
| The Efficacy and Safty of FMT in Patients With CID fecal microbiota, Placebo, synbiotics - Insomnia Chronic, Fecal Microbiota Transplantation | Phase 1 / Phase 2 | Completed | Peking University Sixth Hospital | 80 | 2023-10-08 | 2026-02-27 |
| Neurexan - a Clinical Trial in Short-Term Insomnia Patients Neurexan, Placebo - Insomnia, Stress Reaction | Phase 2 | Completed | Biologische Heilmittel Heel GmbH | 81 | 2023-09-06 | 2026-03-03 |
| A Novel Wearable Device to Improve Sleep Quality Sleep Wellness Device (BeCurie) - Insomnia | Phase 2 | Completed | University of Utah | 59 | 2023-09-01 | 2025-03-28 |
| Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP) Eszopiclone 2 mg, Placebo - Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 42 | 2023-08-31 | 2025-11-25 |
| Cannabinoids as a Treatment for Insomnia in Major Depression 25:1 CBD/THC, 5:1 CBD/THC, Placebo - Insomnia, Depressive Disorder, Major | Phase 2 | Completed | St. Joseph's Healthcare Hamilton | 14 | 2023-08-28 | 2026-01-22 |
| Efficacy and Tolerability of Tasipimidine in Sleepless Patients Tasipimidine, Tasipimidine placebo - Insomnia | Phase 2 | Completed | Orion Corporation, Orion Pharma | 190 | 2023-08-20 | 2025-10-22 |
Showing 20 of 294. Sign in to see all of them.
Sleep Initiation and Maintenance Disorders (118) · Sleep Apnea, Obstructive (75) · Sleep Apnea Syndromes (45) · Restless Legs Syndrome (28) · Disorders of Excessive Somnolence (25) · Sleep Wake Disorders (18) · Narcolepsy (16) · Depression (13) · Hypertension (10) · Anxiety Disorders (9) · Parasomnias (9) · Depressive Disorder, Major (7) · Idiopathic Hypersomnia (7) · Parkinson Disease (7) · Sleep Deprivation (7)
Nervous System Diseases (291) · Sleep Disorders, Intrinsic (281) · Sleep Wake Disorders (276) · Mental Disorders (198) · Respiratory Tract Diseases (107) · Respiration Disorders (102) · Apnea (101) · Pathological Conditions, Signs and Symptoms (68) · Sleep Apnea Syndromes (59) · Signs and Symptoms (55) · Neurologic Manifestations (37) · Parasomnias (28) · Behavior (22) · Central Nervous System Diseases (22)
Continuous Positive Airway Pressure (12) · Zolpidem (10) · Cognitive Behavioral Therapy (9) · Melatonin (9) · Modafinil (9) · ramelteon (9) · Atomoxetine Hydrochloride (8) · solriamfetol (7) · Acetazolamide (6) · Eszopiclone (6) · Sugars (6) · Sodium Oxybate (5) · Probiotics (4) · casopitant (4) · 1-(((alpha-isobutanoyloxyethoxy)carbonyl)aminomethyl)-1-cyclohexaneacetic acid (3)
Brigham and Women's Hospital (17) · Apnimed (10) · GlaxoSmithKline (9) · Takeda (8) · Duke University (7) · University of California, San Diego (7) · Johns Hopkins University (6) · VA Office of Research and Development (6) · Jazz Pharmaceuticals (5) · Stanford University (5) · Boehringer Ingelheim (4) · Idorsia Pharmaceuticals Ltd. (4) · Neurim Pharmaceuticals Ltd. (4) · University of Utah (4) · American Regent, Inc. (3)
United States (192) · Germany (17) · France (14) · Canada (13) · Australia (11) · Spain (8) · Italy (7) · Japan (7) · Netherlands (6) · Switzerland (6) · Belgium (5) · China (4) · Finland (3) · Ireland (3) · Israel (3)
Scott A Sands, PhD (4) · Bradley A Edwards, PhD (3) · Carl J Stepnowsky, PhD (3) · Carlos Camozzi, MD (2) · Christina Barkauskas, MD (2) · Christopher Schmickl, MD, PhD (2) · Dawn M Bravata, MD (2) · Eileen Murphy, PhD (2)
PMID 39688178, PMID 36494591, PMID 41170811, PMID 10341379, PMID 11918106, PMID 12105286, PMID 12126214, PMID 14733976, PMID 15112907, PMID 16491981, PMID 17109795, PMID 17294232, PMID 17352947, PMID 17441783, PMID 17513285, PMID 17520797, PMID 17671050, PMID 17690599, PMID 18457236, PMID 18482867, PMID 18513353, PMID 18555170, PMID 18678823, PMID 18711110, PMID 18753003, PMID 18840807, PMID 18853704, PMID 19054552, PMID 19122865, PMID 19186083, PMID 19192466, PMID 19398354, PMID 19491110, PMID 19581560, PMID 20435443, PMID 20466589, PMID 20620105, PMID 20920156, PMID 21306949, PMID 21397868, PMID 21643649, PMID 21704134, PMID 21705273, PMID 21801857, PMID 21885958, PMID 21886365, PMID 21939549, PMID 22043118, PMID 22131599, PMID 22334806
2015 (3), 2009 (2), 2017 (2), K23HL151880 (2), 1IK2CX000547 (1), 2004 (1), 2014 (1), 2019 (1), K07CA132916 (1), K23AT003678 (1), P01AG021190 (1), P01AG021601 (1), P30AG063786 (1), R01AR052368 (1), R01AT001521 (1)